Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#171 / 199 Total
ALLR - Allarity Therapeutics Inc - Stock Price Chart
TickerALLR [NASD]
CompanyAllarity Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap19.23MEPS (ttm)-708.97
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y84.72%
P/S-EPS next 5Y-
P/B0.70EPS Q/Q99.42%
Dividend-Sales Q/Q-
Insider Own23.57%Inst Own0.61%
Insider Trans0.00%Inst Trans226.28%
Short Float11.17%EarningsNov 14/b
Analyst Recom1.00Target Price8.00
Avg Volume2.18M52W Range0.61 - 103.80
Apr-25-25 08:00AM Allarity Therapeutics Presents Novel Drug Response Predictor DRP for Daratumumab in Multiple Myeloma at AACR 2025 (GlobeNewswire) +5.61%
Mar-31-25 04:05PM Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) -9.91%
Mar-24-25 08:00AM Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares (GlobeNewswire)
Mar-17-25 08:00AM Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology (GlobeNewswire)
Mar-13-25 08:30AM Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission (GlobeNewswire) -11.48%
Mar-06-25 08:00AM Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration (GlobeNewswire)
Mar-03-25 08:00AM Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program (GlobeNewswire) +10.19%
Feb-26-25 08:00AM Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit (GlobeNewswire) +10.17%
Feb-24-25 08:00AM Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients (GlobeNewswire) -13.99%
Feb-06-25 08:00AM Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer (GlobeNewswire)
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
ICG - Intchains Group Ltd ADR - Stock Price Chart
TickerICG [NASD]
CompanyIntchains Group Ltd ADR
CountryChina
IndustrySemiconductors
Market Cap51.56MEPS (ttm)0.12
P/E15.95EPS this Y316.32%
Forward P/E106.18EPS next Y-92.87%
PEG-EPS past 5Y-
P/S1.32EPS next 5Y-
P/B0.80EPS Q/Q59.14%
Dividend-Sales Q/Q110.37%
Insider Own-Inst Own0.05%
Insider Trans-Inst Trans20.80%
Short Float-EarningsFeb 27/a
Analyst Recom1.00Target Price9.50
Avg Volume24.56K52W Range1.40 - 12.04
Intchains Group Ltd. is an ASIC chip design company, which engages in providing integrated solutions consisting of high-performance ASIC chips, and ancillary software and hardware for blockchain applications. It also utilizes a fabless business model and specializes in the front-end and back-end of IC design. The company was founded in December 2017 and is headquartered in Shanghai, China.
DXF - Eason Technology Ltd. ADR - Stock Price Chart
TickerDXF [AMEX]
CompanyEason Technology Ltd. ADR
CountryChina
IndustryCredit Services
Market Cap1.23MEPS (ttm)-1779.92
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.30EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.01%
Insider Trans-Inst Trans-1.02%
Short Float-Earnings-
Analyst Recom-Target Price8.28
Avg Volume414.73K52W Range0.14 - 73.75
Eason Technology Ltd. engages in the provision of loan facilities to micro, small and medium size enterprises, and sole proprietors. It also offers microfinance lending services. The company was founded by Qi Ming Xu and Kang Kai Zeng on June 24, 2010 and is headquartered in Wuhan, China.
APLM - Apollomics Inc - Stock Price Chart
TickerAPLM [NASD]
CompanyApollomics Inc
CountryUSA
IndustryBiotechnology
Market Cap7.24MEPS (ttm)-52.80
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-222.86%
P/S-EPS next 5Y-
P/B34.67EPS Q/Q-1366.67%
Dividend-Sales Q/Q-
Insider Own33.07%Inst Own0.02%
Insider Trans0.00%Inst Trans-95.42%
Short Float1.72%EarningsApr 03/a
Analyst Recom1.00Target Price400.00
Avg Volume23.84K52W Range4.71 - 53.00
Apr-03-25 04:05PM Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress (GlobeNewswire) -16.12% -10.58%
Mar-31-25 08:00AM Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib (GlobeNewswire) -18.53%
Dec-20-24 08:00AM Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Dec-10-24 04:05PM Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement (GlobeNewswire) -14.25% +7.54%
Nov-21-24 08:00AM Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split (GlobeNewswire) -32.58%
Sep-16-24 08:00AM Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-04-24 04:05PM Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +5.13% +5.89%
Aug-14-24 06:00AM Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress (GlobeNewswire)
Aug-13-24 08:00AM Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial (GlobeNewswire) -11.24%
Aug-08-24 04:05PM Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference (GlobeNewswire)
Apollomics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of oncology therapies to address unmet medical needs. The company was founded by Liang Yu Guo and Sanjeev Redkar in 2015 and is headquartered in Foster City, CA.
TANH - Tantech Holdings Ltd - Stock Price Chart
TickerTANH [NASD]
CompanyTantech Holdings Ltd
CountryChina
IndustryHousehold & Personal Products
Market Cap2.72MEPS (ttm)1.16
P/E1.97EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-34.32%
P/S0.06EPS next 5Y-
P/B0.15EPS Q/Q-81.21%
Dividend-Sales Q/Q9.04%
Insider Own8.38%Inst Own0.68%
Insider Trans0.00%Inst Trans-35.68%
Short Float2.09%Earnings-
Analyst Recom-Target Price-
Avg Volume136.96K52W Range1.45 - 63.60
Tantech Holdings Ltd. engages in the development and manufacture of bamboo-based charcoal products. It operates through the Consumer Product and Electric Vehicle segments. The Consumer Product segment manufactures, sell and trade Charcoal Doctor branded products and BBQ charcoal in China well as biodegradable packaging business. The Electric Vehicle segment offers solar cells, lithium-ion batteries, auto parts, and electric control systems. The company was founded by Zheng Yu Wang on November 19, 2010 and is headquartered in Lishui, China.
ACRS - Aclaris Therapeutics Inc - Stock Price Chart
TickerACRS [NASD]
CompanyAclaris Therapeutics Inc
CountryUSA
IndustryDiagnostics & Research
Market Cap145.10MEPS (ttm)-1.51
P/E-EPS this Y60.09%
Forward P/E-EPS next Y-7.73%
PEG-EPS past 5Y15.24%
P/S7.75EPS next 5Y19.73%
P/B0.93EPS Q/Q-4724.29%
Dividend-Sales Q/Q-47.58%
Insider Own15.34%Inst Own68.62%
Insider Trans4.18%Inst Trans274.33%
Short Float4.44%EarningsFeb 27/b
Analyst Recom1.40Target Price7.75
Avg Volume911.62K52W Range0.95 - 5.17
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker NealINTERIM CEODec 04 '24Option Exercise1.52118,840180,6371,501,973Dec 06 04:15 PM
Mehra AnandDirectorNov 19 '24Buy2.25666,6661,499,998710,030Nov 20 04:20 PM
Walker NealINTERIM PRESIDENT AND CEOAug 09 '24Option Exercise0.7243,54831,3551,356,153Aug 13 04:15 PM
Leonard Braden Michael10% OwnerAug 05 '24Buy1.24206,025256,35714,250,000Aug 05 03:57 PM
Leonard Braden Michael10% OwnerAug 02 '24Buy1.29167,544216,40014,043,975Aug 05 03:57 PM
LOAR - Loar Holdings Inc - Stock Price Chart
TickerLOAR [NYSE]
CompanyLoar Holdings Inc
CountryUSA
IndustryAerospace & Defense
Market Cap9.06BEPS (ttm)0.25
P/E393.70EPS this Y75.19%
Forward P/E100.29EPS next Y31.30%
PEG8.07EPS past 5Y-
P/S22.50EPS next 5Y48.77%
P/B8.33EPS Q/Q706.15%
Dividend-Sales Q/Q27.77%
Insider Own22.38%Inst Own79.37%
Insider Trans-23.79%Inst Trans42.04%
Short Float4.16%EarningsMar 31/b
Analyst Recom1.00Target Price92.25
Avg Volume517.86K52W Range42.57 - 96.99
Loar Holdings, Inc. engages in the design, manufacture, and sale of niche aerospace and defense components for aircraft, aerospace and defense systems. The company was founded on August 21, 2017 and is headquartered in White Plains, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEVY PAUL SDirectorDec 12 '24Sale81.17251,61620,424,9299,357,002Dec 16 09:17 PM
Manella Michael J.See RemarksDec 12 '24Sale81.1728,1532,285,320580,388Dec 16 05:26 PM
D'Alessandro GlennSee RemarksDec 12 '24Sale81.1728,5182,314,9491,060,510Dec 16 05:25 PM
MILGRIM BRETT NExecutive Co-ChairmanDec 12 '24Sale81.17120,3059,765,7583,865,327Dec 16 05:18 PM
Charles Dirkson RSee RemarksDec 12 '24Sale81.17126,96010,305,9784,721,377Dec 16 05:17 PM
SCLX - Scilex Holding Company - Stock Price Chart
TickerSCLX [NASD]
CompanyScilex Holding Company
CountryUSA
IndustryDrug Manufacturers - General
Market Cap32.42MEPS (ttm)-0.62
P/E-EPS this Y59.95%
Forward P/E-EPS next Y22.32%
PEG-EPS past 5Y-
P/S0.57EPS next 5Y-
P/B-EPS Q/Q83.55%
Dividend-Sales Q/Q10.68%
Insider Own25.14%Inst Own20.30%
Insider Trans4.23%Inst Trans-
Short Float3.18%EarningsFeb 26
Analyst Recom2.00Target Price446.25
Avg Volume63.73K52W Range3.60 - 80.50
Apr-22-25 09:00AM Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025 (GlobeNewswire) -15.11%
Apr-16-25 02:12PM Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis (GlobeNewswire) -11.56%
Apr-15-25 09:00AM Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB 's Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire)
Apr-12-25 09:51AM Scilex downgraded to Hold from Buy at D. Boral Capital (TipRanks)
Apr-11-25 09:00AM Scilex Holding Company Announces 1-for-35 Reverse Stock Split (GlobeNewswire) -21.53%
Mar-26-25 08:24PM Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva (GlobeNewswire)
Mar-10-25 09:00AM Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025 (GlobeNewswire)
Jan-31-25 09:00AM Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 (GlobeNewswire) -6.39%
Jan-22-25 08:00AM Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication (GlobeNewswire)
Jan-21-25 11:49AM Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) (GlobeNewswire) -5.79%
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHAH JAISIMSee RemarksDec 18 '24Buy0.4630,00013,800139,333Dec 18 07:04 PM
Ji HenryExecutive ChairpersonOct 31 '24Buy0.948,8888,351320,161Oct 31 12:44 PM
SHAH JAISIMSee RemarksOct 29 '24Buy0.9932,00031,670109,333Oct 29 06:59 PM
Followwill DormanDirectorOct 18 '24Buy0.991,0009902,300Oct 18 04:29 PM
Chun JayDirectorOct 18 '24Buy0.955,0004,750112,500Oct 18 04:29 PM
LXU - LSB Industries, Inc - Stock Price Chart
TickerLXU [NYSE, RUT]
CompanyLSB Industries, Inc
CountryUSA
IndustryChemicals
Market Cap406.10MEPS (ttm)-0.27
P/E-EPS this Y151.68%
Forward P/E14.88EPS next Y172.11%
PEG-EPS past 5Y36.70%
P/S0.78EPS next 5Y-
P/B0.82EPS Q/Q-74.32%
Dividend-Sales Q/Q1.73%
Insider Own26.73%Inst Own52.75%
Insider Trans0.00%Inst Trans-1.71%
Short Float3.39%EarningsApr 29/a
Analyst Recom1.33Target Price9.83
Avg Volume422.90K52W Range4.88 - 10.40
LSB Industries, Inc. engages in manufacturing, marketing, and sale of chemical products for the agricultural, mining, and industrial markets. It also own and operate facilities in El Dorado, Arkansas (El Dorado Facility), Cherokee, Alabama (Cherokee Facility), and Pryor, Oklahoma (Pryor Facility), as well as facility for Covestro AG (Covestro) in Baytown, Texas (Baytown Facility). The company was founded by Jack E. Golsen in 1968 and is headquartered in Oklahoma City, OK.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHERYL MAGUIREOfficerOct 10 '24Proposed Sale8.3560,000501,000Oct 10 04:19 PM
BEHRMAN MARK TOfficerOct 10 '24Proposed Sale9.00125,0001,125,000Oct 10 04:07 PM
Foster Michael J.OfficerAug 01 '24Proposed Sale10.0036,000360,000Aug 01 04:07 PM
CARVER KRISTYOfficerAug 01 '24Proposed Sale9.9915,000149,850Aug 01 04:06 PM
Burns JohnEVP - ManufacturingApr 30 '24Sale9.2533,243307,498131,286May 02 04:15 PM
NWTG - Newton Golf Co - Stock Price Chart
TickerNWTG [NASD]
CompanyNewton Golf Co
CountryUSA
IndustryLeisure
Market Cap8.40MEPS (ttm)-74.99
P/E-EPS this Y99.74%
Forward P/E11.53EPS next Y136.96%
PEG-EPS past 5Y-106.30%
P/S2.43EPS next 5Y-
P/B-EPS Q/Q35.06%
Dividend-Sales Q/Q817.09%
Insider Own2.32%Inst Own0.92%
Insider Trans274.07%Inst Trans0.04%
Short Float3.01%EarningsMar 31/b
Analyst Recom-Target Price12.00
Avg Volume3.36M52W Range1.35 - 195.00
Newton Golf Company, Inc. is a technology-forward golf company. It engages in the provision of golf products including putting instruments, golf shafts, golf grips, and other golf-related products. The company was founded by Steve Sacks, Richard Parente, Timothy L. Triplett, and Akinobu Yorihiro in March 2018 and is headquartered in Camarillo, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoge Brett WidneyDirectorApr 15 '25Buy1.8511,14120,61127,033Apr 16 01:29 PM
Hoge Brett WidneyDirectorApr 14 '25Buy1.854,7428,77315,892Apr 15 07:09 PM
Hoge Brett WidneyDirectorApr 11 '25Buy1.854,1177,61611,150Apr 14 12:13 PM
CAMPBELL GREGOR ALASDAIRExecutive ChairmanApr 07 '25Buy3.0232,50098,15035,944Apr 07 08:12 PM
CAMPBELL GREGOR ALASDAIRExecutive ChairmanDec 30 '24Buy0.3625,0009,000103,337Dec 30 04:42 PM
1101314151617181920